Recent Updates
Recently added Catalysts

Diffuse Large B-Cell Lymphoma: 3 biotech companies with clinical-stage programmes

OncologyOrphan cornerData as of 2026-09-04

Competitors3in the clinic
Median market cap$351Muniverse median $1.20B
Allocated capital$834M$1.2B competing
Phase 3 or filed11 mid, 1 early
Pure plays1this indication only
Capital rank160/299crowding rank 69

Diffuse Large B-Cell Lymphoma sits in the orphan corner of the map: 3 developers, none of them large, with a median market cap of $351M against a $1.20B universe median.

A thin field of small caps usually means a narrow addressable population, so the whole field can be repriced by one readout or one financing.

ALLO carries 57% of the $1.2B competing here, more than the other 2 companies combined.

$834M of allocated capital sits in Diffuse Large B-Cell Lymphoma, 160th of 299 indications, and 1 of the 3 companies are pure plays that trade on this indication alone.

Companies developing drugs for Diffuse Large B-Cell Lymphoma 3

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
LYELLyell ImmunopharmaRondecabtagene autoleucelPhase 33$351MNo3 31 Dec 2026
ALLOAllogene Therapeuticscemacabtagene ansegedleucelPhase 21$683MYes1 31 Dec 2026
ADCTADC TherapeuticsLoncastuximab Tesirine and AcalabrutinibPhase 11$168MNo5 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. ALLO holds 57% of the $1.2B competing in this indication.

Why Diffuse Large B-Cell Lymphoma is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Diffuse Large B-Cell Lymphoma has 3 competitors and a median of $351M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Cervical Cancer1 company · $848M · median $2.5BUncontestedCancer Pain1 company · $798M · median $4.0BUncontestedAdvanced EGFR Mutant Non-Small Cell Lung Cancer1 company · $794M · median $794MUncontestedGlioma1 company · $792M · median $2.4BUncontestedMetastatic Head and Neck Squamous Cell Carcinoma1 company · $772M · median $1.5BUncontestedPancreatic Ductal Adenocarcinoma1 company · $768M · median $3.8BUncontestedAdvanced Gastroesophageal Adenocarcinoma1 company · $767M · median $3.8BUncontestedEndometrial Cancer2 companies · $921M · median $2.1BConcentrated bet

Diffuse Large B-Cell Lymphoma pipeline questions

Which biotech companies are developing drugs for Diffuse Large B-Cell Lymphoma?

Lyell Immunopharma (LYEL, Rondecabtagene autoleucel, Phase 3); Allogene Therapeutics (ALLO, cemacabtagene ansegedleucel, Phase 2); ADC Therapeutics (ADCT, Loncastuximab Tesirine and Acalabrutinib, Phase 1). Those are the 3 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Diffuse Large B-Cell Lymphoma.

How advanced is the Diffuse Large B-Cell Lymphoma pipeline?

Of the 3 clinical-stage programmes in Diffuse Large B-Cell Lymphoma, 1 is in Phase 3 or filed, 1 is in mid-stage development and 1 is in early-stage development.

Which company leads the Diffuse Large B-Cell Lymphoma field?

ALLO is the largest developer in Diffuse Large B-Cell Lymphoma, holding 57% of the $1.2B of market capitalisation competing in the indication. The median competitor is worth $351M.

When is the next Diffuse Large B-Cell Lymphoma catalyst?

The next dated catalyst in Diffuse Large B-Cell Lymphoma is LYEL on 31 Dec 2026. 3 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map